123 related articles for article (PubMed ID: 38880878)
1. Association analyses of apolipoprotein E genotypes and cognitive performance in patients with Parkinson's disease.
Zhu SG; Chen ZL; Xiao K; Wang ZW; Lu WB; Liu RP; Huang SS; Zhu JH; Zhang X; Wang JY
Eur J Med Res; 2024 Jun; 29(1):334. PubMed ID: 38880878
[TBL] [Abstract][Full Text] [Related]
2. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.
Shahid M; Kim J; Leaver K; Hendershott T; Zhu D; Cholerton B; Henderson VW; Tian L; Poston KL
Neurobiol Dis; 2019 Jul; 127():278-286. PubMed ID: 30826425
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
4. Evolution and Predictive Role of Plasma Alzheimer's Disease-related Pathological Biomarkers in Parkinson's Disease.
Lin J; Ou R; Li C; Hou Y; Zhang L; Wei Q; Liu K; Jiang Q; Yang T; Xiao Y; Pang D; Zhao B; Chen X; Yang J; Shang H
J Gerontol A Biol Sci Med Sci; 2023 Dec; 78(12):2203-2213. PubMed ID: 37560912
[TBL] [Abstract][Full Text] [Related]
5. Clinical and neurochemical correlates of the APOE genotype in early-stage Parkinson's disease.
Zenuni H; Bovenzi R; Bissacco J; Grillo P; Simonetta C; Mascioli D; Pieri M; Bernardini S; Sancesario GM; Stefani A; Mercuri NB; Schirinzi T
Neurobiol Aging; 2023 Nov; 131():24-28. PubMed ID: 37572524
[TBL] [Abstract][Full Text] [Related]
6. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM
Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
[TBL] [Abstract][Full Text] [Related]
7. The role of APOE in cognitive trajectories and motor decline in Parkinson's disease.
Jo S; Kim SO; Park KW; Lee SH; Hwang YS; Chung SJ
Sci Rep; 2021 Apr; 11(1):7819. PubMed ID: 33837234
[TBL] [Abstract][Full Text] [Related]
8. Plasma apolipoprotein E levels, isoform composition, and dimer profile in relation to plasma lipids in racially diverse patients with Alzheimer's disease and mild cognitive impairment.
Giannisis A; Al-Grety A; Carlsson H; Howell JC; Hu WT; Kultima K; Nielsen HM
Alzheimers Res Ther; 2023 Jul; 15(1):119. PubMed ID: 37400888
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
[TBL] [Abstract][Full Text] [Related]
10. ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly.
Slot RER; Kester MI; Van Harten AC; Jongbloed W; Bouwman FH; Teunissen CE; Scheltens P; van der Flier WM; Veerhuis R
Neurobiol Aging; 2019 Jul; 79():101-109. PubMed ID: 31029938
[TBL] [Abstract][Full Text] [Related]
11. APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.
Tropea TF; Xie SX; Rick J; Chahine LM; Dahodwala N; Doshi J; Davatzikos C; Shaw LM; Van Deerlin V; Trojanowski JQ; Weintraub D; Chen-Plotkin AS
Mov Disord; 2018 Feb; 33(2):289-297. PubMed ID: 29168904
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E ε4 genotype and risk of freezing of gait in Parkinson's disease.
Kim R; Shin JH; Park S; Kim HJ; Jeon B
Parkinsonism Relat Disord; 2020 Dec; 81():173-178. PubMed ID: 33161290
[TBL] [Abstract][Full Text] [Related]
13. Impact of the apolipoprotein E ε4 allele on early Parkinson's disease progression.
Kim R; Park S; Yoo D; Jun JS; Jeon B
Parkinsonism Relat Disord; 2021 Feb; 83():66-70. PubMed ID: 33484977
[TBL] [Abstract][Full Text] [Related]
14. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
[TBL] [Abstract][Full Text] [Related]
15. GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.
Szwedo AA; Dalen I; Pedersen KF; Camacho M; Bäckström D; Forsgren L; Tzoulis C; Winder-Rhodes S; Hudson G; Liu G; Scherzer CR; Lawson RA; Yarnall AJ; Williams-Gray CH; Macleod AD; Counsell CE; Tysnes OB; Alves G; Maple-Grødem J;
Mov Disord; 2022 May; 37(5):1016-1027. PubMed ID: 35106798
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease.
Pu JL; Jin CY; Wang ZX; Fang Y; Li YL; Xue NJ; Zheng R; Lin ZH; Yan YQ; Si XL; Chen Y; Liu Y; Song Z; Yan YP; Tian J; Yin XZ; Zhang BR
Mov Disord; 2022 Jan; 37(1):196-200. PubMed ID: 34612548
[TBL] [Abstract][Full Text] [Related]
17. CSF cutoffs for MCI due to AD depend on APOEε4 carrier status.
Marizzoni M; Ferrari C; Babiloni C; Albani D; Barkhof F; Cavaliere L; Didic M; Forloni G; Fusco F; Galluzzi S; Hensch T; Jovicich J; Marra C; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Ranjeva JP; Ribaldi F; Rolandi E; Rossini PM; Salvatore M; Soricelli A; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB
Neurobiol Aging; 2020 May; 89():55-62. PubMed ID: 32029236
[TBL] [Abstract][Full Text] [Related]
18. Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease.
Ibanez L; Bahena JA; Yang C; Dube U; Farias FHG; Budde JP; Bergmann K; Brenner-Webster C; Morris JC; Perrin RJ; Cairns NJ; O'Donnell J; Álvarez I; Diez-Fairen M; Aguilar M; Miller R; Davis AA; Pastor P; Kotzbauer P; Campbell MC; Perlmutter JS; Rhinn H; Harari O; Cruchaga C; Benitez BA
Acta Neuropathol Commun; 2020 Nov; 8(1):196. PubMed ID: 33213513
[TBL] [Abstract][Full Text] [Related]
19. Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset.
Fiorenzato E; Biundo R; Cecchin D; Frigo AC; Kim J; Weis L; Strafella AP; Antonini A
J Alzheimers Dis; 2018; 66(1):229-237. PubMed ID: 30282359
[TBL] [Abstract][Full Text] [Related]
20. Association of Physical Activity and
Kim R; Park S; Yoo D; Jun JS; Jeon B
Neurology; 2021 May; 96(19):e2429-e2437. PubMed ID: 33790041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
